Table 1 Demographic and clinical characteristics by ACS presentation

Demographics

Age

60.8 +/- 12.5

63.2 +/- 13.0 *

61.0 +/- 13.0 ‡

p = 0.023

Male

70.7%

56.7% *

59.6% †

p < 0.001

Caucasian

85.3%

81.6%

76.5% †

p = 0.08

Insured

84.4%

89.4%

85.6%

p = 0.132

Employed (full or part-time)

46.3%

36.9% *

34.6% †

p = 0.02

Past medical history

History of myocardial infarction

22.1%

24.3%

44.4% †‡

p < 0.001

History of percutaneous coronary intervention

21.8%

27.7%

46.2% †‡

p < 0.001

History of coronary artery bypass graft

10.0%

18.4% *

25% †‡

p < 0.001

Congestive heart failure

3.7%

7.8% *

8.5% †

p = 0.027

Hypertension

56.4%

63.4%

72.7% †‡

p < 0.001

Diabetes mellitus

19.6%

24.6%

32.7% †‡

p < 0.001

Hyperlipidemia

51.1%

58.1%

68.3% †‡

p < 0.001

Transient ischemic attack

1.2%

1.7%

2.1%

p = 0.65

Cerebrovascular accident

0.9%

2.5%

2.7%

p = 0.208

Chronic obstructive pulmonary disease/asthma

5.6%

12.8% §

12.9% †

p = 0.001

Renal failure

0.9%

2.0%

2.7%

p = 0.214

Anemia

62.2%

61.7%

50.2%

p < 0.001

Tobacco use

68.2%

69.9%

73.2% †‡

p < 0.001

Baseline health status

SAQ angina rates

95.0%

87.4% *

93.1% ‡

p < 0.001

SF-12 physical component scores

42.7 +/- 11.4

39.1 +/- 12.3 *

35.3 +/- 11.9 †‡

p < 0.001

SAQ quality of life scores

50.4 +/- 17.3

53.4 +/- 20.2 *

47.0 +/- 18.8 †‡

p < 0.001

ACS therapies

Primary reperfusion

86.3%

65.1% *

42% †‡

p < 0.001

Percutaneous coronary intervention

63.9%

62% §

40.8% †‡

p < 0.001

Lysis

22.4%

3.1% §

1.2% †‡

p < 0.001

Coronary artery bypass graft

4.4%

3.9%

2.9%

p < 0.001

Discharge meds

Angiotensin converting enzyme inhibitors

18.1%

30.2% *

36.5% †‡

p < 0.001

Lipid lowering

79.8%

77.7%

75.2%

p = 0.191

Beta-blockers

87.5%

84.4%

72.5% †‡

p < 0.001

Calcium channel blockers

10.0%

14.2%

23.7% †‡

p < 0.001

Nitrates

9.3%

12.0%

18.1% †‡

p < 0.001

Acetylsalicylic acid (aspirin)

95.9%

93.9%

92.7%

p = 0.379